Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application ...
Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced ...
ERAPs (ERAP1 and ERAP2) are emerging therapeutic targets associated with multiple autoimmune diseases.Genomics will assemble the largest available genetic resource to evaluate how ERAP variants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results